PubMed Health⌕ Search

Biomedical subjects

J Majkowski

Publications and source records attributed to J Majkowski.

At least 91 records · Page 5Linked to original sources
PubMedDate not supplied

[Evaluation of anginine in the treatment of cerebrovascular disorders (preliminary report)].

The effect of Anginin was assessed in 10 patients with cerebrovascular diseases. Anginin was administered in daily doses of 1.5 g. during a mean time of 5.25 months. The duration of follow-up before, during and after treatment was 2 years. A favourable effect of Anginin was observed on such symptoms as dizziness, disturbances of recent memory, mental fatiguability, difficulties in concentration and irritability. EEG investigations demonstrated a rise in the index of alpha waves, increased frequency and amplitude of alpha waves, and normalization of tracings in cases with pathological abnormalities. The basic laboratory investigations failed to reveal any significant changes. Side effects included transient dyspeptic symptoms were in 5 patients.

Aged↗
PubMedDate not supplied

[Effect of diphenylhydantoin on a developed epileptogenic focus in cats with split cerebral hemispheres].

The purpose of this work was to assess the effects of DPH on a developed epileptogenic focus in cats with split cerebral hemispheres. The investigations were carried out on 12 cats with a chronic epileptogenic focus produced by means of aluminum method in the right motor area. In all cats the epileptogenic focus was found in EEG. All animals received DPH in daily doses of 8-15 mg/kg. In 2 cats they appeared before beginning of treatment. One of these cats died after 3 days from status epilepticus, the other survived status epilepticus and died after 42 days of DPH administration with signs of intoxication. In 3 cats clinical seizures developed during DPH treatment after 30.84 and 210 days. DPH was given during from 171 to 314 days. Clinical seizures appeared in these cats only sporadically and the animals were sacrificed after completion of investigations. In 7 out of 12 cats clinical seizures failed to develop despite presence of bioelectrically active epileptogenic seizures in the right motor area. Administration of DPH in cats with developed epileptogenic focus failed to prevent clinical seizures. In cats with seizures their control was limited by drug toxicity. In all animals toxic effects were observed although the serum DPH level was in the range 8-20 mug/ml.

Aluminum↗
PubMedDate not supplied

[Effect of epileptagenic focus on the process of learning and memory in cats].

Investigations were performed on 13 cats with epileptogenic focus developed after sectioning the optic chiasm and corpus callosum. Learning was begun 3 months after producing the epileptogenic focus by the aluminium method when it was bioelectrically active. Additionally in 6 cats DPH in daily doses of 10--15 mg/kg was given 3 months after development of the focus. Learning of these animals was begun 1--2 months after the beginning of DPH administration which was continued throughout the whole period of learning during a 3-month pause in learning, as well as at the time of memory testing. In all animals the time of conditioned reflex development and differentiation was delayed. Learning was more difficult in animals with epileptogenic focus receiving DPH than in the animals with the epileptogenic focus not receiving DPH. Learning was slightly worse in the hemisphere with the focus than in that without the focus. Presence of clinical epileptic seizures was without any significant effect on the time of learning with the exception of days on which clinical seizures occurred (the percent of responses was then lower). Disturbances of memory of acquired conditioned reflexes were found only in animals with clinical seizures.

Animals↗